View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2020	Jul. 30, 2020
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Trading Symbol	SYBX
Entity Registrant Name	SYNLOGIC, INC.
Security Exchange Name	NASDAQ
Entity Central Index Key	0001527599
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Title of 12(b) Security	Common Stock, par value $0.001 per share
Entity Common Stock, Shares Outstanding		34,165,785
Entity Address, State or Province	MA
Entity File Number	001-37566
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	26-1824804
Entity Address, Address Line One	301 Binney St.
Entity Address, Address Line Two	Suite 402
Entity Address, City or Town	Cambridge
Entity Address, Postal Zip Code	02142
City Area Code	617
Local Phone Number	401-9975
Entity Interactive Data Current	Yes
Document Quarterly Report	true
Document Transition Report	false

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 31,350	$ 26,184
Short-term marketable securities	77,786	93,387
Prepaid expenses and other current assets	13,096	13,675
Total current assets	122,232	133,246
Long-term marketable securities		7,502
Property and equipment, net	12,055	13,021
Right of use asset - operating lease	16,416	17,263
Restricted cash	1,097	1,097
Prepaid research and development, net of current portion	7,532	16,381
Other assets	61	64
Total assets	159,393	188,574
Current liabilities:
Accounts payable	1,195	2,165
Accrued expenses	2,432	3,946
Deferred revenue		544
Lease liability - operating lease	2,359	2,000
Finance lease obligations	72	208
Total current liabilities	6,058	8,863
Long-term liabilities:
Lease liability - operating lease, net of current portion	21,581	22,804
Finance lease obligations, net of current portion		2
Other long-term liabilities	82
Total long-term liabilities	21,663	22,806
Commitments and contingencies (Note 11)
Stockholders' Equity
Common stock, $0.001 par value 250,000,000 shares authorized as of March 31, 2020 and December 31, 2019. 32,459,394 and 32,266,814 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively.	34	33
Additional paid-in capital	333,925	327,900
Accumulated other comprehensive loss	214	110
Accumulated deficit	(202,501)	(171,138)
Total stockholders' equity	131,672	156,905
Total liabilities and stockholders' equity	$ 159,393	$ 188,574

Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2020	Dec. 31, 2019
Statement Of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, authorized	250,000,000	250,000,000
Common stock, Issued	34,145,111	32,266,814
Common stock, outstanding	34,145,111	32,266,814

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Statement [Abstract]
Revenue	$ 445	$ 350	$ 545	$ 688
Operating expenses:
Research and development	12,909	9,703	25,586	20,087
General and administrative	3,473	3,742	7,294	7,393
Total operating expenses	16,382	13,445	32,880	27,480
Loss from operations	(15,937)	(13,095)	(32,335)	(26,792)
Other income (expense):
Interest and investment income	406	759	980	1,516
Interest expense	(2)	(5)	(5)	(12)
Other income (expense)	(2)	(3)	(3)	(2)
Other income (expense), net	402	751	972	1,502
Net loss	$ (15,535)	$ (12,344)	$ (31,363)	$ (25,290)
Net loss per share - basic and diluted	$ (0.44)	$ (0.45)	$ (0.91)	$ (0.96)
Weighted-average common stock outstanding - basic and diluted	34,967,761	27,242,514	34,604,738	26,284,262
Comprehensive loss:
Net loss	$ (15,535)	$ (12,344)	$ (31,363)	$ (25,290)
Net unrealized gain (loss) on marketable securities	159	29	104	133
Comprehensive loss	$ (15,376)	$ (12,315)	$ (31,259)	$ (25,157)

Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	At-the-market Offering	Common Stock $0.001 Par Value	Common Stock $0.001 Par Value At-the-market Offering	Additional Paid-in Capital	Additional Paid-in Capital At-the-market Offering	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Balance at Dec. 31, 2018	$ 124,098		$ 25		$ 243,903		$ (65)	$ (119,765)
Balance (in Shares) at Dec. 31, 2018			25,401,479
Proceeds from issuance of common stock, net of issuance costs	56,983		$ 7		56,976
Proceeds from issuance of common stock, net of issuance costs, Shares			6,340,771
Proceeds from pre-funded common stock warrants, net of issuance costs	22,874				22,874
Cancellation of restricted stock			(22,531)
Equity-based compensation expense	2,025				2,025
Unrealized gain (loss) on securities	133						133
Net loss	(25,290)							(25,290)
Balance at Jun. 30, 2019	180,823		$ 32		325,778		68	(145,055)
Balance (in Shares) at Jun. 30, 2019			31,719,719
Balance at Mar. 31, 2019	112,210		$ 25		244,857		39	(132,711)
Balance (in Shares) at Mar. 31, 2019			25,388,643
Proceeds from issuance of common stock, net of issuance costs	56,983		$ 7		56,976
Proceeds from issuance of common stock, net of issuance costs, Shares			6,340,771
Proceeds from pre-funded common stock warrants, net of issuance costs	22,874				22,874
Cancellation of restricted stock			(9,695)
Equity-based compensation expense	1,071				1,071
Unrealized gain (loss) on securities	29						29
Net loss	(12,344)							(12,344)
Balance at Jun. 30, 2019	180,823		$ 32		325,778		68	(145,055)
Balance (in Shares) at Jun. 30, 2019			31,719,719
Balance at Dec. 31, 2019	156,905		$ 33		327,900		110	(171,138)
Balance (in Shares) at Dec. 31, 2019			32,266,814
Proceeds from issuance of common stock, net of issuance costs		$ 3,856		$ 1		$ 3,855
Proceeds from issuance of common stock, net of issuance costs, Shares				1,778,982
Issuance of restricted stock, shares			226,335
Cancellation of restricted stock			(127,020)
Equity-based compensation expense	2,170				2,170
Unrealized gain (loss) on securities	104						104
Net loss	(31,363)							(31,363)
Balance at Jun. 30, 2020	131,672		$ 34		333,925		214	(202,501)
Balance (in Shares) at Jun. 30, 2020			34,145,111
Balance at Mar. 31, 2020	142,117		$ 33		328,995		55	(186,966)
Balance (in Shares) at Mar. 31, 2020			32,459,394
Proceeds from issuance of common stock, net of issuance costs		$ 3,856		$ 1		$ 3,855
Proceeds from issuance of common stock, net of issuance costs, Shares				1,778,982
Cancellation of restricted stock			(93,265)
Equity-based compensation expense	1,075				1,075
Unrealized gain (loss) on securities	159						159
Net loss	(15,535)							(15,535)
Balance at Jun. 30, 2020	$ 131,672		$ 34		$ 333,925		$ 214	$ (202,501)
Balance (in Shares) at Jun. 30, 2020			34,145,111

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash flows from operating activities:
Net loss	$ (31,363)	$ (25,290)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,326	1,356
Equity-based compensation expense	2,170	2,025
Accretion/amortization of investment securities	(29)	(883)
Reduction in carrying amount of operating lease right-of-use asset	848	565
Changes in operating assets and liabilities:
Prepaid expenses and other assets	582	(32,472)
Prepaid research and development, net of current portion	8,849
Accounts payable and accrued expenses	(2,524)	(273)
Deferred revenue	(544)	1,812
Operating lease liabilities	(864)	(544)
Other long-term liabilities	82
Net cash used in operating activities	(21,467)	(53,704)
Cash flows from investing activities:
Purchases of marketable securities	(35,744)	(108,633)
Proceeds from maturity of marketable securities	43,732	89,496
Proceeds from redemption of marketable securities	15,247
Purchases of property and equipment	(320)	(695)
Net cash provided by (used in) investing activities	22,915	(19,832)
Cash flows from financing activities:
Payments on finance lease obligations	(138)	(131)
Proceeds from issuance of common stock, net of issuance costs		56,983
Proceeds from issuance of pre-funded common stock warrants, net of issuance costs		22,874
Net cash provided by financing activities	3,718	79,726
Net increase (decrease) in cash, cash equivalents and restricted cash	5,166	6,190
Cash, cash equivalents and restricted cash at beginning of period	27,281	12,349
Cash, cash equivalents and restricted cash at end of period	32,447	18,539
Supplemental disclosure of non-cash investing and financing activities:
Property and equipment purchases included in accounts payable and accrued expenses	41	(334)
Issuance costs included in accounts payable and accrued expenses	10	100
Cash paid for interest	5	12
Assets acquired under operating lease obligation		$ 1,625
At-the-market Offering
Cash flows from financing activities:
Proceeds from issuance of common stock, net of issuance costs	$ 3,856

Nature of Business

6 Months Ended

Jun. 30, 2020

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Nature of Business

(1)	Nature of Business

Organization

Synlogic, Inc., together with its wholly owned and consolidated subsidiaries (“Synlogic” or the “Company”), is a clinical-stage biopharmaceutical company focused on the discovery and development of Synthetic Biotic™ medicines. Synthetic Biotic medicines are generated from Synlogic’s proprietary drug discovery and development platform, leveraging a reproducible, modular approach to microbial engineering to develop beneficial microbes which perform or deliver critical therapeutic functions. Synthetic Biotic medicines can be designed to sense a local disease context within a patient’s body and respond by metabolizing a toxic substance, compensating for missing or damaged metabolic pathways, or by delivering combinations of therapeutic factors. Synlogic’s goal is to discover, develop, and, ultimately, commercialize Synthetic Biotic medicines. Since incorporation, the Company has devoted substantially all of its efforts to the research and development of its product candidates.

Synlogic, Inc. (“Private Synlogic” when referred to prior to the Merger (as defined below)) was founded and began operations on March 14, 2014, as TMC Therapeutics, Inc., located in Cambridge, Massachusetts. On July 15, 2014, TMC Therapeutics, Inc. changed its name to Synlogic, Inc. On July 2, 2015, the common and preferred stockholders of Private Synlogic executed the Synlogic, LLC Contribution Agreement (the “Contribution Agreement”), pursuant to which such common and preferred stockholders contributed such stockholders’ equity interests in Private Synlogic in exchange for common and preferred units in a newly formed parent company named Synlogic, LLC. In addition, Synlogic IBDCo, Inc. (“IBDCo”) was formed as a subsidiary of Synlogic, LLC (the “2015 Reorganization”). In conjunction with the 2015 Reorganization, Private Synlogic entered into a license, option and merger agreement with AbbVie S.à.r.l. (“AbbVie”), for the development of treatments for inflammatory bowel disease (“IBD”). See Note 9, Collaboration Agreements – AbbVie Collaboration Agreement.

In May 2017, Private Synlogic completed a reorganization (“2017 Reorganization”) pursuant to which Synlogic, LLC merged with and into Private Synlogic, with Private Synlogic continuing as the surviving corporation. Pursuant to the 2017 Reorganization, the common units and preferred units of Synlogic, LLC, together consisting of Class A preferred units, contingently redeemable Class A preferred units and Class B preferred units, were exchanged for common stock and preferred stock of Private Synlogic, respectively. Additionally, Private Synlogic issued equity awards under the Synlogic 2017 Stock Incentive Plan (“2017 Plan”) to replace the canceled incentive units pursuant to the termination of the Synlogic, LLC 2015 Equity Incentive Plan (“2015 LLC Plan”).

On August 28, 2017, Synlogic, Inc., formerly known as Mirna Therapeutics, Inc. (NASDAQ: MIRN) (“Mirna”), completed its business combination with Private Synlogic pursuant to the Agreement and Plan of Merger and Reorganization, dated as of May 15, 2017, by and among Mirna, Meerkat Merger Sub, Inc. (“Merger Sub”), and Private Synlogic (the “Merger Agreement”), pursuant to which Merger Sub merged with and into Private Synlogic, with Private Synlogic surviving as a wholly owned subsidiary of Mirna (the “Merger”). Immediately after completion of the Merger, Mirna changed its name to “Synlogic, Inc.” (NASDAQ: SYBX).

Risks and Uncertainties

At June 30, 2020, the Company had approximately $109.1 million in cash, cash equivalents, and short-term marketable securities, $1.1 million of restricted cash and an accumulated deficit of approximately $202.5 million. Since its inception through June 30, 2020, the Company has primarily financed its operations through the issuance of preferred stock, units and warrants, the sale of its common stock, the AbbVie collaboration, and cash received in the Merger. In the absence of positive cash flows from operations, the Company is highly dependent on its ability to find additional sources of funding in the form of debt or equity financing. Management believes that the Company has sufficient cash to fund its operations through at least twelve months from the issuance of these financial statements.

As an early-stage company, the Company is subject to a number of risks common to other life science companies, including, but not limited to, raising additional capital, development by its competitors of new technological innovations, risk of failure in preclinical and clinical studies, safety and efficacy of its product candidates in clinical trials, the risk of relying on external parties such as contract research organizations (“CROs”) and contract manufacturing organizations (“CMOs”), the regulatory approval process, market acceptance of the Company’s products once approved, lack of marketing and sales history, dependence on key personnel and protection of proprietary technology. The Company’s therapeutic programs are currently pre-commercial, spanning discovery through early development and will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization of any product candidates. These efforts require significant amounts of additional capital, adequate personnel, infrastructure, and extensive compliance-reporting capabilities. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be obtained, that any products developed will obtain necessary regulatory approval or that any approved products will be commercially viable. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company may never achieve profitability, and unless and until it does, it will continue to need to raise additional capital or obtain financing from other sources, such as strategic collaborations or partnerships.

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2020

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

(2)	Summary of Significant Accounting Policies

The significant accounting policies described in the Company’s audited financial statements as of and for the year ended December 31, 2019, and the notes thereto, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the Securities and Exchange Commission (“SEC”) on March 12, 2020 (the “2019 Annual Report”), have had no material changes during the three and six months ended June 30, 2020. The updated accounting policy and the impact of adoption are discussed in the “Recently Adopted Accounting Pronouncements” section in this note.

Basis of Presentation

The accompanying consolidated financial statements and the related disclosures as of June 30, 2020 and for the three and six months ended June 30, 2020 and 2019 are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and the rules and regulations of the SEC for interim financial statements. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. These interim consolidated financial statements should be read in conjunction with the Company’s 2019 and 2018 audited consolidated financial statements and notes included in the Company’s 2019 Annual Report. The December 31, 2019 consolidated balance sheet included herein was derived from the audited financial statements as of that date but does not include all disclosures including notes required by GAAP for complete financial statements. In the opinion of management, the unaudited interim consolidated financial statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for the fair presentation of the Company’s financial position and results of operations for the three and six months ended June 30, 2020 and 2019. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the year ending December 31, 2020 or any other interim period or future year or period.

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of Synlogic and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

Recently Adopted Accounting Pronouncements

In December 2019, the FASB issued ASU 2019-12 – Income Taxes – (Topic 740): Simplifying the Accounting for Income Taxes, which provides amended guidance on income tax accounting. The amended guidance is effective for fiscal years beginning after December 15, 2020, including interim periods within that fiscal year. Early adoption is permitted. The amended guidance, which simplifies the accounting for income taxes, includes the removal of exceptions to the general principles of ASC 740. The standard removed the exception to the incremental approach for intra-period tax allocation when there is a loss from continuing operations and income or a gain from other items. The Company adopted the new guidance effective on January 1, 2020 which had an immaterial impact on its consolidated financial statements.

Recently Issued Accounting Pronouncements

In June 2016, the FASB issued ASU 2016-13 - Measurement of Credit Losses on Financial Statements. The new standard requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. It also limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value increases. In November 2019, the FASB issued ASU 2019-10 – Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates, which amended the effective date for certain companies. The standard is effective for public companies eligible to be smaller reporting companies for annual and interim periods beginning after December 15, 2022. Early adoption is available. The Company is currently evaluating the potential impact ASU 2016-13, and related updates, will have on its consolidated financial statements and disclosures.

Fair Value of Financial Instruments

6 Months Ended

Jun. 30, 2020

Fair Value Disclosures [Abstract]

Fair Value of Financial Instruments

(3)	Fair Value of Financial Instruments

The tables below present information about the Company’s assets that are measured at fair value on a recurring basis and indicate the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value, as described under Note 2, Summary of Significant Accounting Policies, in the audited financial statements included in the Company’s 2019 Annual Report.

The Company’s investment portfolio includes many fixed income securities that do not always trade on a daily basis. As a result, the pricing services used by the Company applied other available information as applicable through processes such as benchmark yields, benchmarking of like securities, sector groupings and matrix pricing to prepare evaluations. In addition, model processes were used to assess interest rate impact and develop prepayment scenarios. These models take into consideration relevant credit information, perceived market movements, sector news and economic events. The inputs into these models may include benchmark yields, reported trades, broker-dealer quotes, issuer spreads and other relevant data.

At June 30, 2020 and December 31, 2019, the Company has classified assets measured at fair value on a recurring basis as follows (in thousands):

	Fair Value Measurements at Reporting Date Using
	June 30,		Quoted Prices in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs
Description	2020		(Level 1)		(Level 2)		(Level 3)
Money market funds	$	17,852	$	17,852	$	—	$	—
Commercial paper (included in marketable securities)		32,948		—		32,948		—
Corporate debt securities (included in marketable securities)		43,831		—		43,831		—
U.S. government agency securities and treasuries		1,006		—		1,006		—
Total	$	95,637	$	17,852	$	77,785	$	—

	Fair Value Measurements at Reporting Date Using
	December 31,		Quoted Prices in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs
Description	2019		(Level 1)		(Level 2)		(Level 3)
Money market funds	$	3,240	$	3,240	$	—	$	—
Commercial paper (included in cash and cash equivalents)		4,249		—		4,249		—
Commercial paper (included in marketable securities)		20,501		—		20,501		—
Corporate debt securities (included in cash and cash equivalents)		6,005		—		6,005		—
Corporate debt securities (included in marketable securities)		71,383		—		71,383		—
U.S. government agency securities and treasuries		9,005		—		9,005		—
Total	$	114,383	$	3,240	$	111,143	$	—

Cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses at June 30, 2020 and December 31, 2019 are carried at amounts that approximate fair value due to their short-term maturities. Finance lease obligations at June 30, 2020 and December 31, 2019 approximate fair value as they bear interest at a rate approximating a market interest rate.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Available-for-Sale Investments

6 Months Ended

Jun. 30, 2020

Investments Debt And Equity Securities [Abstract]

Available-for-Sale Investments

(4)	Available-for-Sale Investments

The following tables summarize the available-for-sale securities held at June 30, 2020 and December 31, 2019 (in thousands):

June 30, 2020	Amortized cost		Gross unrealized gains		Gross unrealized losses			Fair Value
Commercial paper	$	32,880	$	73	$	(5	)	$	32,948
Corporate debt securities		43,691		141		—			43,832
U.S. government agency securities		1,001		5		—			1,006
Total	$	77,572	$	219	$	(5	)	$	77,786

December 31, 2019	Amortized cost		Gross unrealized gains		Gross unrealized losses			Fair Value
Commercial paper	$	20,484	$	18	$	(1	)	$	20,501
Corporate debt securities		71,288		96		(1	)		71,383
U.S. government agency securities		9,005		2		(2	)		9,005
Total	$	100,777	$	116	$	(4	)	$	100,889

The contractual maturity of all securities held at June 30, 2020 was 11 months or less. There were four and nine investments in an unrealized loss position at June 30, 2020 and December 31, 2019, respectively, none of which had been in an unrealized loss position for more than twelve months. The aggregate fair value of the securities in an unrealized loss position at June 30, 2020 and December 31, 2019 was $14.0 million and $24.8 million, respectively. The Company reviews its investments for other-than-temporary impairment whenever the fair value of an investment is less than amortized cost and evidence indicates that an investment’s carrying amount is not recoverable within a reasonable period of time. To determine whether an impairment is other-than-temporary, the Company considers whether it has the ability and intent to hold the investment until a market price recovery and considers whether evidence indicating the cost of the investment is recoverable outweighs evidence to the contrary. The Company did not hold any securities with an other-than-temporary impairment at June 30, 2020.

Gross realized gains and losses on the sales of investments have not been material to the Company’s consolidated statement of operations.

Property and Equipment, Net

6 Months Ended

Jun. 30, 2020

Property Plant And Equipment [Abstract]

Property and Equipment, Net

(5)	Property and Equipment, net

Property and equipment, net consists of the following (in thousands):

	June 30,			December 31,
	2020			2019
Laboratory equipment	$	7,780		$	7,523
Computer and office equipment		782			782
Furniture and fixtures		421			421
Leasehold improvements		9,514			9,514
Construction in progress		516			412
	$	19,013			18,652
Less accumulated depreciation		(6,958	)		(5,631	)
	$	12,055		$	13,021

Accrued Expenses

6 Months Ended

Jun. 30, 2020

Payables And Accruals [Abstract]

Accrued Expenses

(6)	Accrued Expenses

Accrued expenses consist of the following (in thousands):

	June 30,		December 31,
	2020		2019
Payroll related	$	1,848	$	2,372
Professional fees		418		444
Research and development		102		1,005
Other		64		125
	$	2,432	$	3,946

Stockholders' Equity

6 Months Ended

Jun. 30, 2020

Equity [Abstract]

Stockholders' Equity

(7)	Stockholders’ Equity

In June 2019, the Company issued to Ginkgo Bioworks, Inc. an aggregate of 6,340,771 shares of common stock at a purchase price per share of $9.00, and pre-funded warrants (the “Pre-Funded Warrants”) to purchase an aggregate of 2,548,117 shares of common stock at an exercise price of $9.00 per share, with $8.99 of such exercise price paid at the closing of the offering. The net proceeds to the Company were approximately $79.9 million.

The Pre-Funded Warrants may be exercised at any time until all of the Pre-Funded Warrants are exercised in full to the extent that, after giving effect to such issuance after exercise, Ginkgo would not beneficially own in excess of 19.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance.

The Pre-Funded Warrants were classified as a component of permanent equity and were recorded at the issuance date using a relative fair value allocation method. The Pre-Funded Warrants are equity classified because they are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the holders to receive a fixed number of common shares upon exercise. In addition, such warrants do not provide any guarantee of value or return. None of the Pre-Funded Warrants have been exercised as of June 30, 2020.

On October 13, 2017 the Company entered into a sales agreement with Cowen and Company, LLC (“Cowen”) with respect to an at-the-market (“ATM”) offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, through Cowen as its sales agent. In an ATM offering, exchange-listed companies incrementally sell newly issued shares into the secondary trading market through a designated broker-dealer at prevailing market prices. During the three month period ended June 30, 2020, 1,778,982 shares of common stock were sold pursuant to the ATM, resulting in net proceeds of approximately $3.9 million.

Equity-based Compensation and Equity Incentive Plans

6 Months Ended

Jun. 30, 2020

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Equity-based Compensation and Equity Incentive Plans

(8)	Equity‑based Compensation and Equity Incentive Plans

The Company is displaying all equity in its post-Merger amounts.

Equity Plans

The Company currently has three active equity plans.

The 2015 Equity Incentive Award Plan (the “2015 Plan”) was adopted by Mirna in 2015 and remains active after the Merger, now functioning as the primary equity plan for the Company. The 2015 Plan provides for the granting of a variety of stock‑based compensation awards, including stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, deferred stock awards, dividend equivalent awards, stock payment awards, performance awards and other stock‑based awards. Pursuant to the evergreen provision of the 2015 Plan, which allows for an annual increase in the number of shares of common stock available for issuance, the Company added 1,613,340 shares to the 2015 Plan on January 1, 2020.

The 2017 Stock Incentive Plan (the “2017 Plan”) was adopted by Private Synlogic in 2017 at the time of the 2017 Reorganization and assumed by the Company during the Merger. The 2017 Plan provides for the grant of incentive stock options, non-qualified stock options, restricted and unrestricted stock awards and other stock-based awards.

The 2015 Employee Stock Purchase Plan (“ESPP”) was adopted by Mirna in 2015 and allows eligible employees to purchase shares of the Company’s common stock at a discount through payroll deductions of up to 15% of their eligible compensation, subject to any plan limitations. The ESPP generally provides for set offering periods, and at the end of each offering period, employees are able to purchase shares at 85% of the lower of the fair market value of the Company’s common stock on the first trading day of the offering period or on the last trading day of the offering period. The Company suspended the ESPP in 2017. In December 2019, the Board reactivated the ESPP and approved an amendment to the ESPP to (i) reduce the permitted aggregate yearly payroll deduction and maximum number of shares of the Company’s common stock that a participant may purchase per offering period under the ESPP and (ii) establish a period for enrollment for eligible participants. The reactivation of the ESPP was effective immediately. The Company’s executive officers are eligible to participate in the ESPP. There were no options to purchase shares of common stock under the ESPP exercised as of June 30, 2020.

As of June 30, 2020, there were 1,300,740 shares available for future grant under the 2017 Plan and the 2015 Plan, and 375,519 shares available for future grant under the ESPP.

For a full description of the Company’s equity plans, refer to Note 9, Equity-based Compensation and Equity Incentive Plans in the Company’s 2019 Annual Report.

Stock Options

The following table summarizes stock option activity during the six months ended June 30, 2020 under the 2015 Plan and the 2017 Plan.

	Stock options outstanding
						Weighted
				Weighted		average		Aggregate
				average		remaining		Intrinsic
	Number of			exercise		contractual		value^(a)
	options			price		term (in years)		(in thousands)
Outstanding at December 31, 2019		2,286,419		$	9.24		8.7	$	43
Granted		1,184,863			1.82				—
Forfeited		(295,190	)		6.93				43
Outstanding at June 30, 2020		3,176,092			6.69		8.7	$	290

Vested or expected to vest at June 30, 2020		3,176,092			6.69		8.7		290

Exercisable at June 30, 2020		1,137,599			10.42		7.9	$	11

(a)	The aggregate intrinsic value is calculated as the difference between the exercise price of the options and the fair market value of the underlying common stock for the options that were in the money at June 30, 2020 and December 31, 2019.

As of June 30, 2020, there was $5.5 million of unrecognized share-based compensation related to unvested stock option grants which is expected to be recognized over a weighted average period of 2.2 years. The total unrecognized share-based compensation cost will be adjusted for actual forfeitures as they occur.

Restricted Common Stock

The following table shows restricted stock activity during the six months ended June 30, 2020:

	Restricted stock awards
				Grant date
	Number of			fair value
	shares			(per share)
Unvested at December 31, 2019		586,929		$	2.97
Granted		226,335			1.70
Vested		(17,104	)		13.56
Forfeited		(127,020	)		2.36
Unvested at June 30, 2020		669,140		$	2.38

As of June 30, 2020, there was approximately $0.9 million of unrecognized share-based compensation related to restricted stock awards granted, which is expected to be recognized over a weighted average period of 1.8 years. The total unrecognized share-based compensation cost will be adjusted for actual forfeitures as they occur.

Employee Stock Purchase Plan

The ESPP is considered a compensatory plan with the related compensation cost expensed over the six-month offering period starting on April 1 and ending on October 1. The compensation cost for the three and six months ended June 30, 2020 was $12,000. There was no compensation expense related to the ESPP for the three and six months ended June 30, 2019.

Equity Compensation

The Company has recorded total equity-based compensation expense of approximately $1.1 million and $2.2 million during the three and six months ended June 30, 2020, respectively and $1.1 million and $2.0 million during the three and six months ended June 30, 2019, respectively.

The following table summarizes equity‑based compensation expense within the Company’s consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2020 and 2019 (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Research and development	$	486	$	349	$	927	$	633
General and administrative		589		722		1,243		1,392
	$	1,075	$	1,071	$	2,170	$	2,025

The following table summarizes equity‑based compensation expense by type of award for the three and six months ended June 30, 2020 and 2019 (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Stock options	$	890	$	1,047	$	1,765	$	1,973
Restricted stock awards		173		24		393		52
Employee stock purchase plan		12		—		12		—
	$	1,075	$	1,071	$	2,170	$	2,025

Collaboration Agreements

6 Months Ended

Jun. 30, 2020

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Collaboration Agreements

(9)	Collaboration Agreements

Ginkgo Collaboration

In 2017, the Company established a technology collaboration with Ginkgo Bioworks, Inc. (“Ginkgo”). In June 2019, in connection with the issuance to Ginkgo of an aggregate of 6,340,771 shares of common stock and Pre-Funded warrants to purchase an aggregate of 2,548,117 common stock (See Note 7), the Company expanded its collaboration and entered into an agreement with Ginkgo for the research and development of engineered microbial therapeutic products. Under the 2019 expanded agreement, the Company made a prepayment to Ginkgo of $30.0 million for its foundry services that will be provided to the Company over an initial term of five years. The prepayment of foundry services is recorded in Prepaid expenses and other current assets and Prepaid research and development, net of current portion on the June 30, 2020 consolidated balance sheet. At June 30, 2020, the Company had remaining balances of $11.5 million and $6.9 million of current and non-current pre-paid research and development costs related to this transaction, respectively. Upon the expiration of such initial term and, if applicable, an additional period, any portion of the prepayment that has not been used to purchase services from Ginkgo will be retained by Ginkgo.

AbbVie Collaboration Agreement

In July 2015, the Company entered into the AbbVie Agreement under which the Company granted AbbVie an exclusive option to purchase IBDCo and, in exchange, agreed to collaborate in researching and developing an Investigational New Drug (“IND”) candidate for the treatment of IBD. The AbbVie Agreement sets forth the Company’s and AbbVie’s respective obligations for development and delivery of an IND candidate package using reasonable commercial efforts.

In May 2020, we announced the termination of our collaboration with AbbVie to develop Synthetic Biotic medicines for the treatment of types of IBD, including Crohn’s disease and ulcerative colitis. Upon termination, we regained all rights to develop these and new IBD Synthetic Biotic medicines for all effectors targeting IBD. This allows us to fully leverage our expertise in strain engineering, quantitative biology, regulatory, and manufacturing to expand our wholly owned GI-based program portfolio to include IBD. We further regained the rights to partner these IBD programs.

Under the now terminated collaboration, in exchange for the exclusive option to acquire IBDCo, initial research and development services for drug discovery and pre-clinical development, and participation on the joint research committee (“JRC”), AbbVie agreed to pay IBDCo an upfront, non-refundable cash payment of $2.0 million, which IBDCo received in December 2015. AbbVie also agreed to pay IBDCo up to $16.5 million in milestone payments associated with specified research and pre-clinical events, which were determined to represent customer options for accounting purposes, as well as an option exercise fee upon the execution of their option to buy IBDCo and other royalty and milestone payments. The upfront cash payment and any payments for option fees and royalties are non-refundable, non-creditable and not subject to set-off.

The research and development was performed by the Company over four phases of research defined in the research plan. The Company is eligible to receive payments from AbbVie upon the election to continue the research and development at the achievement of certain milestone events. The JRC was tasked with making a determination as to the continuation of the collaboration at the achievement of research and pre-clinical milestones, except for the final milestone, which AbbVie had the discretion to determine achievement without the approval of the JRC. If the parties make the determination to continue on with the AbbVie Agreement upon achievement of each milestone event, then AbbVie would have had to pay the consideration associated with that milestone and the collaboration would have continued through the remaining term of the option to purchase IBDCo, which was initially considered to be approximately 54 months.

The Company assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, AbbVie, was considered a customer. The Company identified the following material promises at the outset of the arrangement: (1) a non-exclusive royalty-free research and development license; (2) research and development services for pre-clinical activities under the research plan through to the first research and development phase (or an estimated 17 months); (3) three option rights for AbbVie to continue the collaboration as related to three phases of research and development; (4) participation on the JRC; and (5) the transfer of ownership of IBDCo upon exercise of the option to buy IBDCo. The Company determined that the license and research and development activities were not distinct from one another. Participation on the JRC to oversee the research and development activities was determined to be quantitatively and qualitatively immaterial and therefore is excluded from performance obligations. As such, the Company determined that the license and research and development services should be combined into a single performance obligation.

The Company evaluated the milestone payments, which represent customer options as described above, and the option to purchase IBDCo, to determine whether they provide AbbVie with any material rights. The Company concluded that the options were not issued at a significant and incremental discount, and therefore do not provide material rights. As such, they were excluded as performance obligations at the outset of the arrangement. If AbbVie elects to exercise the options, the additional consideration will be added to the transaction price and allocated to the resulting performance obligations.

Based on these assessments, the Company identified one performance obligation at the outset of the AbbVie Agreement, which consists of: (1) the non-exclusive license and (2) the research and development activities through the first research and development phase.

At the outset of the arrangement, the transaction price included only the $2.0 million up-front consideration received which was allocated to the single performance obligation. The option exercise fees ($16.5 million for the milestones and the IBDCo purchase option exercise fee) that may have been received were excluded from the transaction price until each customer option was exercised. The Company reevaluated the transaction price at the end of each reporting period and as uncertain events were resolved or other changes in circumstances occurred, and, if necessary, adjusted our estimate of the transaction price.

In May 2017, the Company completed the research and development services for the first phase of the research plan and was paid $2.0 million to commence the second phase of the research plan. At this time, the $2.0 million was added to the transaction price and allocated to a new performance obligation consisting of the underlying license and research and development services to be performed over the second phase of the research plan.

On September 27, 2018, AbbVie and the Company signed an amendment (the “Second Amendment”) to the AbbVie Agreement. The Second Amendment clarified the requirements necessary to complete the second phase which resulted in additional time and effort in the second phase of the research plan. Additionally, the Second Amendment split the next milestone payment under the AbbVie Agreement into two payments: a milestone payment of $2.0 million earned by the Company upon execution of the Second Amendment and the remaining milestone payment of the balance due upon the successful achievement of specified research and pre-clinical events and the advancement to the third phase of the research plan.

On December 18, 2018, AbbVie and the Company signed an amendment (the “Third Amendment”) to the AbbVie Agreement. The Third Amendment provided that in the event AbbVie determined that it was necessary to enter into license agreements with certain third parties in a particular country or other jurisdiction which, but for such license, would be infringed by the manufacture, use or sale of any product governed by the AbbVie Agreement, AbbVie would have been entitled to deduct certain expenses related to such license agreements from particular payments made to the Company.

The Company determined that the Amendment represented a modification to the AbbVie Agreement. The additional research and development services were not distinct from the remaining research and development services under the second phase of the research plan of the AbbVie Agreement. The Amendment was accounted for as part of the original AbbVie Agreement and the services form part of the single performance obligation that was partially satisfied as of the date of the contract modification. As a result, the transaction price for the current performance obligation associated with the second phase of the research plan increased by $2.0 million. The impact of the contract modification on the transaction price and the measure of progress toward completion of the performance obligation was recognized as an adjustment to revenue upon execution of the Amendment on a cumulative catch-up basis. The cumulative catch-up adjustment to revenue, as a result of the contract modification, was $1.8 million during 2018.

On February 28, 2019, the JRC concluded that the remaining milestone of $2.5 million under the Second Amendment was achieved upon the achievement of specified research and pre-clinical events under the second phase of the research plan and the advancement to the third phase of the research plan. Revenue associated with performance obligations under the AbbVie Agreement is recognized as the research and development services are provided using an input method, according to the full-time equivalents incurred. The transfer of control occurs over time and, in management’s judgment, is the best measure of progress towards satisfying the performance obligation. The amounts received that have not yet been recognized as revenue are recorded in deferred revenue on the Company’s consolidated balance sheet.

Revenue associated with performance obligations under the AbbVie Agreement are recognized as the research and development services are provided using an input method, according to the full-time equivalents incurred. The research and development activities are expected to be performed over a period of approximately 54 months. The transfer of control occurs over time and, in management’s judgment, is the best measure of progress towards satisfying the performance obligation. The amounts received that have not yet been recognized as revenue are recorded in deferred revenue on the Company’s consolidated balance sheet.

The Company recognized revenue of $0.4 million for the three months ended June 30, 2020 and 2019, respectively, and the Company recognized revenue of $0.5 million and $0.7 million for the six months ended June 30, 2020 and 2019, respectively, as collaboration revenue in the Company’s consolidated statements of operations and comprehensive loss. There is no deferred revenue on the Company’s consolidated balance sheet as of June 30, 2020, as the remainder of the revenue was recognized when the agreement was terminated.

Net Loss per Share

6 Months Ended

Jun. 30, 2020

Earnings Per Share [Abstract]

Net Loss per Share

(10)	Net Loss per Share

Basic net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the sum of the weighted-average number of shares of common stock outstanding during the period and if dilutive, the weighted-average number of potential shares of common stock, including unvested restricted common stock and outstanding stock options. In June 2019, the Company sold 6,340,771 shares of common stock and Pre-Funded Warrants to purchase an aggregate of 2,548,117 shares of common stock at an exercise price of $9.00 per share, with $8.99 of such exercise price paid at the closing of the offering (see Note 10, Ginkgo Collaboration, in the audited financial statements included in the Company’s 2019 Annual Report). The shares of common stock into which the warrants may be exercised are considered outstanding for the purposes of computing net loss per share.

The Company’s potentially dilutive shares, which include outstanding stock options and unvested restricted common stock/units, are considered to be common share equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.

The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of the diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect.

	As of June 30,
	2020		2019
Unvested restricted common stock awards		669,140		62,919
Outstanding options to purchase common stock		3,176,092		2,509,746

Commitments and Contingencies

6 Months Ended

Jun. 30, 2020

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

(11)	Commitments and Contingencies

In the ordinary course of business, the Company may be subject to legal proceedings, claims and litigation as the Company operates in an industry susceptible to patent legal claims. The Company accounts for estimated losses with respect to legal proceedings and claims when such losses are probable and estimable. Legal costs associated with these matters are expensed when incurred. The Company is not currently a party to any material legal proceedings.

The Company’s commitments described in the Company’s consolidated financial statements as of and for the year ended December 31, 2019 and the notes thereto included in the Company’s Annual Report on Form 10-K filed with the SEC on March 12, 2020, have had no material changes during the six months ended June 30, 2020.

Related-Party Transactions

6 Months Ended

Jun. 30, 2020

Related-Party Transactions

(12)	Related-Party Transactions

In June 2019, the Company expanded its collaboration and entered into an agreement with Ginkgo for the research and development of engineered microbial therapeutic products. As of June 30, 2020, Ginkgo owns 6,340,771 shares of the Company’s outstanding common stock. See Note 10, Ginkgo Collaboration, in the audited financial statements included in the Company’s 2019 Annual Report.

Under the agreement the Company made a prepayment to Ginkgo of $30.0 million for its foundry services that will be provided to the Company over an initial term of five years. At June 30, 2020, the Company had remaining balances of $11.5 million and $6.9 million of current and non-current pre-paid research and development costs related to this transaction, respectively. The Company used $5.3 million and $8.9 million of the pre-paid research and development expenses for the three and six months ended June 30, 2020, respectively.

Summary of Significant Accounting Policies (Policies)	6 Months Ended
Summary of Significant Accounting Policies (Policies)	Jun. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements and the related disclosures as of June 30, 2020 and for the three and six months ended June 30, 2020 and 2019 are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and the rules and regulations of the SEC for interim financial statements. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. These interim consolidated financial statements should be read in conjunction with the Company’s 2019 and 2018 audited consolidated financial statements and notes included in the Company’s 2019 Annual Report. The December 31, 2019 consolidated balance sheet included herein was derived from the audited financial statements as of that date but does not include all disclosures including notes required by GAAP for complete financial statements. In the opinion of management, the unaudited interim consolidated financial statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for the fair presentation of the Company’s financial position and results of operations for the three and six months ended June 30, 2020 and 2019. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the year ending December 31, 2020 or any other interim period or future year or period.
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include the accounts of Synlogic and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12 – Income Taxes – (Topic 740): Simplifying the Accounting for Income Taxes, which provides amended guidance on income tax accounting. The amended guidance is effective for fiscal years beginning after December 15, 2020, including interim periods within that fiscal year. Early adoption is permitted. The amended guidance, which simplifies the accounting for income taxes, includes the removal of exceptions to the general principles of ASC 740. The standard removed the exception to the incremental approach for intra-period tax allocation when there is a loss from continuing operations and income or a gain from other items. The Company adopted the new guidance effective on January 1, 2020 which had an immaterial impact on its consolidated financial statements.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13 - Measurement of Credit Losses on Financial Statements. The new standard requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. It also limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value increases. In November 2019, the FASB issued ASU 2019-10 – Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates, which amended the effective date for certain companies. The standard is effective for public companies eligible to be smaller reporting companies for annual and interim periods beginning after December 15, 2022. Early adoption is available. The Company is currently evaluating the potential impact ASU 2016-13, and related updates, will have on its consolidated financial statements and disclosures.

Fair Value of Financial Instruments (Tables)

6 Months Ended

Jun. 30, 2020

Fair Value Disclosures [Abstract]

Schedule of Company's Classified Assets Measured at Fair Value on Recurring Basis

At June 30, 2020 and December 31, 2019, the Company has classified assets measured at fair value on a recurring basis as follows (in thousands):

	Fair Value Measurements at Reporting Date Using
	June 30,		Quoted Prices in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs
Description	2020		(Level 1)		(Level 2)		(Level 3)
Money market funds	$	17,852	$	17,852	$	—	$	—
Commercial paper (included in marketable securities)		32,948		—		32,948		—
Corporate debt securities (included in marketable securities)		43,831		—		43,831		—
U.S. government agency securities and treasuries		1,006		—		1,006		—
Total	$	95,637	$	17,852	$	77,785	$	—

	Fair Value Measurements at Reporting Date Using
	December 31,		Quoted Prices in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs
Description	2019		(Level 1)		(Level 2)		(Level 3)
Money market funds	$	3,240	$	3,240	$	—	$	—
Commercial paper (included in cash and cash equivalents)		4,249		—		4,249		—
Commercial paper (included in marketable securities)		20,501		—		20,501		—
Corporate debt securities (included in cash and cash equivalents)		6,005		—		6,005		—
Corporate debt securities (included in marketable securities)		71,383		—		71,383		—
U.S. government agency securities and treasuries		9,005		—		9,005		—
Total	$	114,383	$	3,240	$	111,143	$	—

Available-for-Sale Investments (Tables)

6 Months Ended

Jun. 30, 2020

Investments Debt And Equity Securities [Abstract]

Summary of Available-for-Sale Securities Held

The following tables summarize the available-for-sale securities held at June 30, 2020 and December 31, 2019 (in thousands):

June 30, 2020	Amortized cost		Gross unrealized gains		Gross unrealized losses			Fair Value
Commercial paper	$	32,880	$	73	$	(5	)	$	32,948
Corporate debt securities		43,691		141		—			43,832
U.S. government agency securities		1,001		5		—			1,006
Total	$	77,572	$	219	$	(5	)	$	77,786

December 31, 2019	Amortized cost		Gross unrealized gains		Gross unrealized losses			Fair Value
Commercial paper	$	20,484	$	18	$	(1	)	$	20,501
Corporate debt securities		71,288		96		(1	)		71,383
U.S. government agency securities		9,005		2		(2	)		9,005
Total	$	100,777	$	116	$	(4	)	$	100,889

Property and Equipment, Net (Tables)

6 Months Ended

Jun. 30, 2020

Property Plant And Equipment [Abstract]

Schedule of Property and Equipment, Net

Property and equipment, net consists of the following (in thousands):

	June 30,			December 31,
	2020			2019
Laboratory equipment	$	7,780		$	7,523
Computer and office equipment		782			782
Furniture and fixtures		421			421
Leasehold improvements		9,514			9,514
Construction in progress		516			412
	$	19,013			18,652
Less accumulated depreciation		(6,958	)		(5,631	)
	$	12,055		$	13,021

Accrued Expenses (Tables)

6 Months Ended

Jun. 30, 2020

Payables And Accruals [Abstract]

Schedule of Accrued Expenses

Accrued expenses consist of the following (in thousands):

	June 30,		December 31,
	2020		2019
Payroll related	$	1,848	$	2,372
Professional fees		418		444
Research and development		102		1,005
Other		64		125
	$	2,432	$	3,946

Equity-based Compensation and Equity Incentive Plans (Tables)

6 Months Ended

Jun. 30, 2020

Schedule of Restricted Common Stock Activity

The following table shows restricted stock activity during the six months ended June 30, 2020:

	Restricted stock awards
				Grant date
	Number of			fair value
	shares			(per share)
Unvested at December 31, 2019		586,929		$	2.97
Granted		226,335			1.70
Vested		(17,104	)		13.56
Forfeited		(127,020	)		2.36
Unvested at June 30, 2020		669,140		$	2.38

Schedule of Equity-based Compensation Expenses

	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Research and development	$	486	$	349	$	927	$	633
General and administrative		589		722		1,243		1,392
	$	1,075	$	1,071	$	2,170	$	2,025

Schedule of Equity-based Compensation Expenses by Award Type

The following table summarizes equity‑based compensation expense by type of award for the three and six months ended June 30, 2020 and 2019 (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Stock options	$	890	$	1,047	$	1,765	$	1,973
Restricted stock awards		173		24		393		52
Employee stock purchase plan		12		—		12		—
	$	1,075	$	1,071	$	2,170	$	2,025

2015 and 2017 Plan

Schedule of Stock Option Activity

The following table summarizes stock option activity during the six months ended June 30, 2020 under the 2015 Plan and the 2017 Plan.

	Stock options outstanding
						Weighted
				Weighted		average		Aggregate
				average		remaining		Intrinsic
	Number of			exercise		contractual		value^(a)
	options			price		term (in years)		(in thousands)
Outstanding at December 31, 2019		2,286,419		$	9.24		8.7	$	43
Granted		1,184,863			1.82				—
Forfeited		(295,190	)		6.93				43
Outstanding at June 30, 2020		3,176,092			6.69		8.7	$	290

Vested or expected to vest at June 30, 2020		3,176,092			6.69		8.7		290

Exercisable at June 30, 2020		1,137,599			10.42		7.9	$	11

(a)	The aggregate intrinsic value is calculated as the difference between the exercise price of the options and the fair market value of the underlying common stock for the options that were in the money at June 30, 2020 and December 31, 2019.

Net Loss per Share (Tables)

6 Months Ended

Jun. 30, 2020

Earnings Per Share [Abstract]

Schedule of Potentially Common Shares Excluded from Calculation of Net Loss Per share

	As of June 30,
	2020		2019
Unvested restricted common stock awards		669,140		62,919
Outstanding options to purchase common stock		3,176,092		2,509,746

Nature of Business - Additional Information (Detail) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Cash, cash equivalents, and short-term marketable securities	$ 109,100
Restricted cash	1,097	$ 1,097
Accumulated deficit	$ (202,501)	$ (171,138)

Fair Value of Financial Instruments - Schedule of Company's Classified Assets Measured at Fair Value on Recurring Basis (Detail) - Recurring - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Fair Value Asset Measured On Recurring Basis [Line Items]
Total assets	$ 95,637	$ 114,383
Money market funds
Fair Value Asset Measured On Recurring Basis [Line Items]
Cash and Cash Equivalents	17,852	3,240
Commercial paper
Fair Value Asset Measured On Recurring Basis [Line Items]
Cash and Cash Equivalents		4,249
Marketable securities	32,948	20,501
U.S. Government Agency Securities and Treasuries
Fair Value Asset Measured On Recurring Basis [Line Items]
Short-term investments	1,006	9,005
Corporate debt securities
Fair Value Asset Measured On Recurring Basis [Line Items]
Cash and Cash Equivalents		6,005
Marketable securities	43,831	71,383
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Asset Measured On Recurring Basis [Line Items]
Total assets	17,852	3,240
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Money market funds
Fair Value Asset Measured On Recurring Basis [Line Items]
Cash and Cash Equivalents	17,852	3,240
Significant Other Observable Inputs (Level 2)
Fair Value Asset Measured On Recurring Basis [Line Items]
Total assets	77,785	111,143
Significant Other Observable Inputs (Level 2) \| Commercial paper
Fair Value Asset Measured On Recurring Basis [Line Items]
Cash and Cash Equivalents		4,249
Marketable securities	32,948	20,501
Significant Other Observable Inputs (Level 2) \| U.S. Government Agency Securities and Treasuries
Fair Value Asset Measured On Recurring Basis [Line Items]
Short-term investments	1,006	9,005
Significant Other Observable Inputs (Level 2) \| Corporate debt securities
Fair Value Asset Measured On Recurring Basis [Line Items]
Cash and Cash Equivalents		6,005
Marketable securities	43,831	71,383
Significant Unobservable Inputs (Level 3)
Fair Value Asset Measured On Recurring Basis [Line Items]
Total assets	0	0
Significant Unobservable Inputs (Level 3) \| Money market funds
Fair Value Asset Measured On Recurring Basis [Line Items]
Cash and Cash Equivalents	0	0
Significant Unobservable Inputs (Level 3) \| Commercial paper
Fair Value Asset Measured On Recurring Basis [Line Items]
Cash and Cash Equivalents		0
Marketable securities	0	0
Significant Unobservable Inputs (Level 3) \| U.S. Government Agency Securities and Treasuries
Fair Value Asset Measured On Recurring Basis [Line Items]
Short-term investments	0	0
Significant Unobservable Inputs (Level 3) \| Corporate debt securities
Fair Value Asset Measured On Recurring Basis [Line Items]
Cash and Cash Equivalents		0
Marketable securities	$ 0	$ 0

Available-for-Sale Investments - Summary of Available-for-Sale Securities Held (Detail) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	$ 77,572	$ 100,777
Gross unrealized gains	219	116
Gross unrealized losses	(5)	(4)
Fair Value	77,786	100,889
Commercial paper
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	32,880	20,484
Gross unrealized gains	73	18
Gross unrealized losses	(5)	(1)
Fair Value	32,948	20,501
Corporate debt securities
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	43,691	71,288
Gross unrealized gains	141	96
Gross unrealized losses		(1)
Fair Value	43,832	71,383
U.S. government agency securities
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	1,001	9,005
Gross unrealized gains	5	2
Gross unrealized losses		(2)
Fair Value	$ 1,006	$ 9,005

Available-for-Sale Investments - Additional Information (Detail) $ in Millions	Jun. 30, 2020 USD ($) Investment Security	Dec. 31, 2019 USD ($) Investment
Investments Debt And Equity Securities [Abstract]
Number of investments in unrealized loss position	4	9
Number of investments in unrealized loss position, more than twelve months	0	0
Aggregate fair value of securities in unrealized loss position \| $	$ 14.0	$ 24.8
Number of securities with other than temporary impairment \| Security	0

Property and Equipment, Net - Schedule of Property and Equipment, Net (Detail) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 19,013	$ 18,652
Less accumulated depreciation	(6,958)	(5,631)
Property and equipment, net	12,055	13,021
Laboratory Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	7,780	7,523
Computer and Office Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	782	782
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Property and equipment, gross	421	421
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and equipment, gross	9,514	9,514
Construction in Progress
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 516	$ 412

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Payables And Accruals [Abstract]
Payroll related	$ 1,848	$ 2,372
Professional fees	418	444
Research and development	102	1,005
Other	64	125
Total accrued expenses	$ 2,432	$ 3,946

Stockholders Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2019
Class Of Stock [Line Items]
Proceeds from issuance of common stock, net of issuance costs				$ 56,983
Common Stock
Class Of Stock [Line Items]
Proceeds from issuance of common stock, net of issuance costs, Shares	6,340,771		6,340,771	6,340,771
Pre-Funded Warrants
Class Of Stock [Line Items]
Warrants to purchase shares of common stock	2,548,117		2,548,117	2,548,117
Warrants exercise price per share	$ 9.00		$ 9.00	$ 9.00
Warrants exercise price per share paid at closing of offering	8.99		8.99	8.99
Ginkgo Bioworks, Inc.
Class Of Stock [Line Items]
Exercise price of warrants, per share	$ 9.00		$ 9.00	$ 9.00
Proceeds from issuance of common stock and pre-funded warrants	$ 79,900
Ginkgo Bioworks, Inc. \| Common Stock
Class Of Stock [Line Items]
Proceeds from issuance of common stock, net of issuance costs, Shares	6,340,771
Ginkgo Bioworks, Inc. \| Pre-Funded Warrants
Class Of Stock [Line Items]
Warrants exercised		0
Ginkgo Bioworks, Inc. \| Pre-Funded Warrants \| Maximum
Class Of Stock [Line Items]
Unbeneficial percentage of ownership after exercise of common stock outstanding effect to issuance	19.99%
Ginkgo Bioworks, Inc. \| Pre-Funded Warrants
Class Of Stock [Line Items]
Warrants to purchase shares of common stock	2,548,117		2,548,117	2,548,117
Warrants exercise price per share	$ 9.00		$ 9.00	$ 9.00
Warrants exercise price per share paid at closing of offering	$ 8.99		$ 8.99	$ 8.99
Cowen and Company, LLC \| ATM
Class Of Stock [Line Items]
Proceeds from issuance of common stock, net of issuance costs, Shares		1,778,982
Proceeds from issuance of common stock, net of issuance costs		$ 3,900

Equity-based Compensation and Equity Incentive Plans - Additional Information (Detail) - USD ($)		3 Months Ended		6 Months Ended
	Jan. 01, 2020	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee unrecognized compensation expense		$ 5,500,000		$ 5,500,000
Employee unrecognized compensation cost, period of recognition				2 years 2 months 12 days
Equity-based compensation expense		1,075,000	$ 1,071,000	$ 2,170,000	$ 2,025,000
Restricted Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee unrecognized compensation expense		900,000		$ 900,000
Employee unrecognized compensation cost, period of recognition				1 year 9 months 18 days
Equity-based compensation expense		$ 173,000	24,000	$ 393,000	52,000
ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of discount for employees under ESPP				15.00%
Purchase price as a percentage of fair value under ESPP				85.00%
Options to purchase shares of common stock under ESPP exercised				0
Shares available for future grants		375,519		375,519
Equity-based compensation expense		$ 12,000	$ 0	$ 12,000	$ 0
Plan 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Increase in number of shares available for issuance (in shares)	1,613,340
2015 and 2017 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future grants		1,300,740		1,300,740

Equity-based Compensation and Equity Incentive Plans - Schedule of Stock Option Activity Under 2015 and 2017 Plan (Detail) - 2015 and 2017 Plan - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Beginning balance, Number of options	2,286,419
Granted, Number of options	1,184,863
Forfeited, Number of options	(295,190)
Outstanding Ending balance, Number of options	3,176,092
Number of options, Vested or expected to vest	3,176,092
Number of options, Exercisable	1,137,599
Beginning balance, Weighted-average price	$ 9.24
Granted, Weighted-average price	1.82
Forfeited, Weighted-average price	6.93
Ending balance, Weighted-average price	6.69
Weighted-average price Vested or expected to vest	6.69
Weighted-average price, Exercisable	$ 10.42
Outstanding, weighted average remaining contractual term (Year)	8 years 8 months 12 days	8 years 8 months 12 days
Weighted average remaining contractual term, Vested or expected to vest	8 years 8 months 12 days
Weighted average remaining contractual term, Exercisable	7 years 10 months 24 days
Beginning balance, Aggregate Intrinsic value	$ 43
Forfeited, Aggregate Intrinsic value	43
Ending balance, Aggregate Intrinsic value	290
Aggregate Intrinsic value, Vested or expected to vest at June 30, 2020	290
Aggregate Intrinsic value, Exercisable at June 30, 2020	$ 11

Equity-based Compensation and Equity Incentive Plans - Schedule of Restricted Common Stock Activity (Detail) - Restricted Common Stock	6 Months Ended
	Jun. 30, 2020 $ / shares shares
Beginning balance, Number of unvested shares/units \| shares	586,929
Granted, Number of shares/units \| shares	226,335
Vested, Number of shares/units \| shares	(17,104)
Forfeited, Number of shares/units \| shares	(127,020)
Ending balance, Number of unvested shares/units \| shares	669,140
Beginning balance, Unvested Grant date fair value \| $ / shares	$ 2.97
Granted, Grant date fair value \| $ / shares	1.70
Vested, Grant date fair value \| $ / shares	13.56
Forfeited, Grant date fair value \| $ / shares	2.36
Ending balance, Unvested Grant date fair value \| $ / shares	$ 2.38

Equity-based Compensation and Equity Incentive Plans - Schedule of Equity-based Compensation Expenses (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Equity-based compensation expense	$ 1,075	$ 1,071	$ 2,170	$ 2,025
Research and Development Expense
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Equity-based compensation expense	486	349	927	633
General and Administrative Expense
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Equity-based compensation expense	$ 589	$ 722	$ 1,243	$ 1,392

Equity-based Compensation and Equity Incentive Plans - Schedule of Equity-based Compensation Expenses by Award Type (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Equity-based compensation expense	$ 1,075	$ 1,071	$ 2,170	$ 2,025
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Equity-based compensation expense	890	1,047	1,765	1,973
Restricted Stock Awards
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Equity-based compensation expense	173	$ 24	393	$ 52
ESPP
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Equity-based compensation expense	$ 12		$ 12

Collaboration Agreements - Additional Information (Detail)		1 Months Ended			3 Months Ended		6 Months Ended		12 Months Ended
	Sep. 27, 2018 USD ($) Milestone	Jun. 30, 2019 USD ($) shares	May 31, 2017 USD ($)	Dec. 31, 2015 USD ($)	Jun. 30, 2020 USD ($)	Jun. 30, 2019 USD ($) shares	Jun. 30, 2020 USD ($)	Jun. 30, 2019 USD ($) shares	Dec. 31, 2018 USD ($)	Dec. 31, 2019 USD ($)	Feb. 28, 2019 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Recognition of revenue					$ 445,000	$ 350,000	$ 545,000	$ 688,000
Current deferred revenue										$ 544,000
Pre-Funded Warrants
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Warrants to purchase shares of common stock \| shares		2,548,117				2,548,117		2,548,117
Common Stock
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of shares sold \| shares		6,340,771				6,340,771		6,340,771
Ginkgo Collaboration
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Prepayment to related party for collaboration agreement		$ 30,000,000.0
Related party transaction collaboration agreement, initial term		5 years
Current pre-paid research and development					11,500,000		11,500,000
Non-current pre-paid research and development					6,900,000		6,900,000
Ginkgo Collaboration \| Pre-Funded Warrants
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Warrants to purchase shares of common stock \| shares		2,548,117				2,548,117		2,548,117
Ginkgo Collaboration \| Common Stock
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of shares sold \| shares		6,340,771
AbbVie Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of mile stone payments under second phase \| Milestone	2
Initial milestone payment upon execution of amendment	$ 2,000,000.0
Increase in transaction price of performance obligation of second phase	$ 2,000,000.0
Cumulative catch-up adjustment to revenue, contract modification									$ 1,800,000
Remaining milestone achieved											$ 2,500,000
Recognition of revenue					400,000	$ 400,000	500,000	$ 700,000
Current deferred revenue					$ 0		0
AbbVie Agreement \| IBDCo
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront non-refundable payment				$ 2,000,000.0
Potential milestone payment							$ 16,500,000
Collaboration in research and development							54 months
Milestone payment			$ 2,000,000.0

Net Loss per Share - Additional Information (Detail)	1 Months Ended	3 Months Ended	6 Months Ended
Net Loss per Share - Additional Information (Detail)	Jun. 30, 2019 $ / shares shares	Jun. 30, 2019 $ / shares shares	Jun. 30, 2019 $ / shares shares
Common Stock
Number of shares sold \| shares	6,340,771	6,340,771	6,340,771
Pre-Funded Warrants
Warrants to purchase shares of common stock \| shares	2,548,117	2,548,117	2,548,117
Warrants exercise price per share \| $ / shares	$ 9.00	$ 9.00	$ 9.00
Warrants exercise price per share paid at closing of offering \| $ / shares	$ 8.99	$ 8.99	$ 8.99

Net Loss per Share - Schedule of Potentially Common Shares Excluded from Calculation of Net Loss Per share (Detail) - shares	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Unvested Restricted Common Stock Awards
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potentially Common Shares Excluded from Calculation of Net Loss Per share	669,140	62,919
Stock Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potentially Common Shares Excluded from Calculation of Net Loss Per share	3,176,092	2,509,746

Related-Party Transactions - Additional Information (Detail) - USD ($) $ in Millions	1 Months Ended	3 Months Ended	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2020	Dec. 31, 2019
Related Party Transaction [Line Items]
Common stock, outstanding		34,145,111	34,145,111	32,266,814
Ginkgo Bioworks, Inc.
Related Party Transaction [Line Items]
Common stock, outstanding		6,340,771	6,340,771
Prepayment to related party for collaboration agreement	$ 30.0
Related party transaction collaboration agreement, initial term	5 years
Current Pre-Paid Research and Development		$ 11.5	$ 11.5
Non Current Pre-Paid Research and Development		6.9	6.9
Prepaid research and development expenses		$ 5.3	$ 8.9